Mealey's ( June 2, 2025, 3:18 PM EDT) -- YAKIMA, Wash. — The U.S. Food and Drug Administration argues in a May 30 reply brief on its cross-motion for summary judgment filed in a Washington federal court that only the state established that it is entitled to seek judicial relief in a suit filed by a group of states over the agency’s decision to add Risk Evaluation and Mitigation Strategy (REMS) restrictions on mifepristone XE "mifepristone" , one of the two drugs prescribed for medication abortions....